Latest News
View More
The big interview: Cisco UK and Ireland CEO David Meads
Foreseeing a global pandemic is not in any business leader’s job description. But perhaps the most vital skill for today’s…
Latest News
View More
Innovent’s HCC therapy trial meets primary endpoints
Innovent Biologics has reported positive interim analysis results from Phase III ORIENT-32 study of anti-PD-1 antibody-based combination therapy versus sorafenib for treating patients with advanced…
Eisai reports dose comparison data from Lenvima thyroid cancer trial
Eisai has reported results from the Phase II Study 211 of two doses of its orally available multiple receptor tyrosine kinase inhibitor, Lenvima, in patients…
Clear Creek Bio initiates dosing for Covid-19 drug trial
Clear Creek Bio has dosed the first patient in the Phase II CRISIS2 study of brequinar to treat patients with…
University of Wisconsin initiates paediatric neuroblastoma trial
The University of Wisconsin School of Medicine and Public Health in the US has initiated a first-in-human clinical trial for…
Pfizer reports positive data from lung cancer drug trial
Pfizer has reported positive interim analysis results from the Phase III CROWN trial of Lorbrena (lorlatinib) versus Xalkori (crizotinib) in…
MS Society recruits participants for trial on people who cannot walk
The MS Society in the UK has announced that recruitment of patients will start next year in the multiple sclerosis…
Expert Commentary & Analysis
View MoreIncrease of resumed trials slowing due to Covid-19 cases rising
Since early March, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due to the Covid-19 pandemic. Many companies have delayed the initiation of…
Brainstorm’s NurOwn fails Phase III trial, demonstrating the struggle to develop effective ALS treatment
On 17 November, Brainstorm Cell Therapeutics announced topline results for its anticipated amyotrophic lateral sclerosis (ALS) stem cell therapy, NurOwn, as its Phase III trial did not reach statistically significant…
Eli Lilly’s monoclonal antibody bamlanivimab value allows payer grace for Covid-19
by Manasi Vaidya in New York Eli Lilly’s Covid-19 monoclonal antibody (mAb) bamlanivimab is unlikely to face payer pushback, despite its broad label, after a recent FDA emergency use authorisation…
Registration of head-to-head psoriatic arthritis clinical trial begins the battle for second place
On 17 November 2020, Novartis registered a Phase III psoriatic arthritis (PsA) clinical trial of its IL-17 inhibitor Cosentyx (secukinumab) compared against Johnson & Johnson’s Stelara (ustekinumab). The 28-week study…